Xenon Pharmaceuticals (XENE) Net Margin (2013 - 2025)

Xenon Pharmaceuticals' (XENE) quarterly Net Margin came in at 867.29% in Q1 2025, up 96.92% on a QoQ basis from 28143.94% in Q3 2022.

Xenon Pharmaceuticals (XENE) Net Margin (2013 - 2025) Analysis & Trends

Xenon Pharmaceuticals (XENE) has 10 years of Net Margin data on file, last reported at 867.29% in Q1 2025.

On a quarterly basis, Net Margin changed N/A year-over-year to 867.29% in Q1 2025; TTM through Dec 2025 was 4737.05%, a N/A change from a year earlier, with the FY2025 full-year figure at 4737.05%, changed N/A from the prior year.
Net Margin for Q1 2025 stood at 867.29%, up from 28143.94% in the prior quarter.
Over the last five years, Net Margin for XENE reached as high as 185.66% in Q3 2021 and fell as low as 28143.94% in Q3 2022.
Historically, Net Margin has averaged 4653.41% across 3 years, with a median of 769.17% in 2021.
On a YoY basis, Net Margin climbed as much as 13104 bps in 2022 and fell as far as 2795828 bps in 2022.
Year by year, Net Margin stood at 671.05% in 2021, then sank by 4094 bps to 28143.94% in 2022, then jumped by 97 bps to 867.29% in 2025.
Per Business Quant data, the three most recent Net Margin figures were 867.29% in Q1 2025, 28143.94% in Q3 2022, and 5813.06% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	15.02%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	34.53%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	20.17%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	30.33%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Xenon Pharmaceuticals	5.71 Bn	5.71 Bn	-	-

Download Data